|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||64.18 - 66.03|
|52 Week Range||51.39 - 72.58|
|PE Ratio (TTM)||49.95|
|Earnings Date||Apr 26, 2018|
|Forward Dividend & Yield||0.64 (0.98%)|
|1y Target Est||75.87|
Baxter International (BAX) announced the completion of its acquisition of Recothrom and Preveleak assets from Mallinckrodt Pharmaceuticals (MNK) for a total consideration of $185.0 million. This transaction includes $153.0 million in upfront payments and the rest in future milestone-based payments. Additionally, Baxter International has assumed Preveleak’s associated expenses and the contingent liabilities. Preveleak’s manufacturing operations are also included in the deal.
STAINES-UPON-THAMES, United Kingdom, March 19, 2018 /PRNewswire/ -- Mallinckrodt plc (MNK), a leading specialty pharmaceutical company, announced today it has closed the sale of RECOTHROM® Thrombin topical (Recombinant) and PREVELEAK® Surgical Sealant to Baxter International Inc. (BAX). "This action further illustrates the strategic evolution of our portfolio, and will free resources for investing in treatments for seriously ill infants and adults," said Mark Trudeau, President and Chief Executive Officer of Mallinckrodt. The approximately $185 million transaction consists of a base payment of $153 million, inclusive of existing inventory and subject to a closing inventory adjustment, and the remainder in potential future milestones.
Baxter International Inc. , a global medical products company, is committed to advancing surgical innovation and today announced it has completed its previously announced acquisition of two hemostat and sealant products from Mallinckrodt plc.
Dentsply Sirona (XRAY) updated its estimates and assumptions during fiscal 2Q17 and underwent an annual impairment test of goodwill. According to company estimates, the goodwill charges associated with some of its technologies segment businesses, including CAD-CAM imaging and its treatment center, came from impairment. The company recorded nearly $1.1 billion in goodwill impairment charges in 2Q17 and $581 million in 4Q17, for a total of ~$1.67 billion in fiscal 2017. Meanwhile, the company undertook an annual impairment assessment of indefinite-lived intangible assets.
Mallinckrodt (MNK) shares gained as the company beat both earnings and revenue estimates in the fourth quarter as Inomax sales revived somewhat.
Abiomed (ABMD) is strategically focused on the market penetration of the company’s family of Impella heart pumps. The Impella device portfolio consists of Impella 2.5, Impella CP, Impella RP, Impella LD, and Impella 5.0 devices. To this end, Abiomed discontinued the sale of its AB5000 device used for heart surgery.
Abiomed (ABMD) is a supplier of mechanical circulatory support devices and offers a continuum of care to heart failure patients. Abiomed develops, manufactures, and commercializes products designed to improve the blood flow and perform the pumping function of the heart. Of the ten analysts covering Abiomed (ABMD) in February 2018, five analysts have given the stock a “strong buy” rating, three analysts have given it a “buy” rating, while two analysts have given it a “hold” rating.
When Baxter International Inc (NYSE:BAX) released its most recent earnings update (31 December 2017), I compared it against two factor: its historical earnings track record, and the performance of itsRead More...
Baxter International Inc (NYSE:BAX) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.
Headquartered in Lawrence, Massachusetts, NxStage Medical (NXTM) is a medical technology company with a focus on developing, manufacturing, and marketing innovative products targeted at patients suffering from chronic or acute kidney failure. The company also operates NxStage kidney care dialysis centers, which treat end-stage renal disease (or ESRD) patients. NxStage Medical’s primary product is System One, which is capable of delivering the therapeutic flexibility and clinical benefits of traditional dialysis machines in a smaller, portable, and easy-to-use format.
Stock Monitor: iRhythm Technologies Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 22, 2018 / Active-Investors.com has just released a free earnings report on Baxter International Inc. (NYSE: ...
NEW YORK, Feb. 21, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Timken ...
Baxter International Inc. today announced a quarterly cash dividend and an expanded authorization for its share repurchase program.
Baxter International Inc. will present at the Barclays Global Healthcare Conference on Tuesday, March 13, 2018, in Miami, Fla. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 10:15 a.m.